Melinda Telli's guest appearances

Melinda Telli

Breast Cancer Update

Research To Practice | Oncology Videos

Matthew R Smith

Tumor Panel

Sara Hurvitz

Eric P Winer

Ingrid A Mayer

Emmanuel S Antonarakis

Harold J Burstein

Joyce O’Shaughnessy

Erica L Mayer

Sara M Tolaney

Daniel F Hayes

Lisa A Carey

Matthew Goetz

Virginia Kaklamani

Johanna Bendell

OwlTail

Breast Cancer Update, Issue 4, 2019 — Part 2: Our interview with Dr Telli highlights the following topics as well as cases from her practice:  Case: A woman in her early 50s with de novo metastatic TNBC is enrolled on the IMpassion130 trial evaluating atezolizumab with nab paclitaxel (00:00) Initial workup and genetic testing for patients with metastatic TNBC (02:33) Risk of recurrence for patients with localized TNBC; patterns of metastasis (05:11) Approach to PD-L1 testing for patients with TNBC (07:29) Results of the Phase III IMpassion130 study of atezolizumab with nab paclitaxel for previously untreated advanced TNBC (10:41) Clinical implications of the IMpassion130 study results (14:57) Perspective on progression-free and overall survival outcomes with atezolizumab/nab paclitaxel (16:59) Clinical experience with atezolizumab and nab paclitaxel as first-line therapy for advanced TNBC (19:05) Tolerability of atezolizumab in the IMpassion130 trial (23:52) Activity of single-agent pembrolizumab in patients with TNBC (25:28) Emerging data with pembrolizumab in combination with chemotherapy for TNBC in the (neo)adjuvant setting (27:58) Evaluation of anti-PD-L1 antibodies in the neoadjuvant setting (31:03) Case: A woman in her late 20s with a family history of breast cancer and a germline BRCA mutation receives talazoparib and avelumab on a clinical trial for metastatic TNBC (33:17) Efficacy and tolerability of platinum regimens for patients with TNBC (35:25) Results from the OlympiAD (olaparib) and EMBRACA (talazoparib) trials for patients with HER2-negative advanced breast cancer and a germline BRCA mutation (42:40) Activity and side-effect profile of olaparib versus talazoparib (46:43) Ongoing investigation of the combination of anti-PD-1/PD-L1 antibodies and PARP inhibitors (49:47) Sequencing PARP inhibitors for patients with PD-L1-negative breast cancer (53:03) Use of PARP inhibitors for patients with breast cancer and mutations in DNA damage repair genes beyond BRCA (55:52) Tolerability of PARP inhibitors for patients with germline BRCA mutations (1:00:35)   CME information and select publications

Breast Cancer Update, Issue 4, 2019 — Part 2: Our interview with Dr Telli highlights the following topics as well as cases from her practice: <ul> <li>Case: A woman in her early 50s with de novo metastatic TNBC is enrolled on the IMpassion130 trial evaluating atezolizumab with nab paclitaxel (00:00)</li> <li>Initial workup and genetic testing for patients with metastatic TNBC (02:33)</li> <li>Risk of recurrence for patients with localized TNBC; patterns of metastasis (05:11)</li> <li>Approach to PD-L1 testing for patients with TNBC (07:29)</li> <li>Results of the Phase III IMpassion130 study of atezolizumab with nab paclitaxel for previously untreated advanced TNBC (10:41)</li> <li>Clinical implications of the IMpassion130 study results (14:57)</li> <li>Perspective on progression-free and overall survival outcomes with atezolizumab/nab paclitaxel (16:59)</li> <li>Clinical experience with atezolizumab and nab paclitaxel as first-line therapy for advanced TNBC (19:05)</li> <li>Tolerability of atezolizumab in the IMpassion130 trial (23:52)</li> <li>Activity of single-agent pembrolizumab in patients with TNBC (25:28)</li> <li>Emerging data with pembrolizumab in combination with chemotherapy for TNBC in the (neo)adjuvant setting (27:58)</li> <li>Evaluation of anti-PD-L1 antibodies in the neoadjuvant setting (31:03)</li> <li>Case: A woman in her late 20s with a family history of breast cancer and a germline BRCA mutation receives talazoparib and avelumab on a clinical trial for metastatic TNBC (33:17)</li> <li>Efficacy and tolerability of platinum regimens for patients with TNBC (35:25)</li> <li>Results from the OlympiAD (olaparib) and EMBRACA (talazoparib) trials for patients with HER2-negative advanced breast cancer and a germline BRCA mutation (42:40)</li> <li>Activity and side-effect profile of olaparib versus talazoparib (46:43)</li> <li>Ongoing investigation of the combination of anti-PD-1/PD-L1 antibodies and PARP inhibitors (49:47)</li> <li>Sequencing PARP inhibitors for patients with PD-L1-negative breast cancer (53:03)</li> <li>Use of PARP inhibitors for patients with breast cancer and mutations in DNA damage repair genes beyond BRCA (55:52)</li> <li>Tolerability of PARP inhibitors for patients with germline BRCA mutations (1:00:35)</li> </ul> <a href="http://m.researchtopractice.com/BCU419/Video?playlistIndex=0#t=0m0s" rel="nofollow" target="_blank"> CME information and select publications</a>

Breast Cancer | Melinda Telli, MD

Breast Cancer Update - Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Interview with Melinda Telli, MD conducted by Neil Love, MD. Produced by Research To Practice.

Breast Cancer Update 4 2019 | Interview with Melinda Telli, MD on the Management of Triple-Negative Breast Cancer